Synthetic TLR9 ligands have also been investigated in preclinical models of brain cancer immunotherapy; CpG-sequence containing oligonucleotides were shown to induce apoptosis in brain cancer cells in vitro and in vivo and, therefore, may provide long-term antitumor immunity against gliomas (22,23). The gene discussed is TLR9; the disease is brain cancer.